The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133a

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Steeg PS. Targeting metastasis. Nature Reviews Cancer. 2016;16:201–218.
   PubMed Web of Science ®Google Scholar
• Yang Z, Li X, Yang Y, et al. Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death Dis. 2016;7:e2389.
   PubMed Web of Science ®Google Scholar
• Khaitan D, Dinger ME, Mazar J, et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011;71:3852–3862.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu S, Cai G, et al. Long non coding RNA MALAT1 promotes tumor growth and metastasis by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. Sci Rep. 2015;5:15972.
   PubMed Web of Science ®Google Scholar
• Zhou X, Ye F, Yin C, et al. The interaction between MiR-141 and lncRNA-H19 in regulating cell proliferation and migration in gastric cancer. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2015;36:1440–1452.
   PubMed Web of Science ®Google Scholar
• Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer Manag. 2016;139:269–280.
   PubMed Web of Science ®Google Scholar
• Li C, Miao R, Liu S, et al. Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis. Oncotarget. 2017;8:28683–28695.
   PubMedGoogle Scholar
• Luan W, Li R, Liu L, et al. Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p. Oncotarget. 2017;8:85401–85414.
   PubMedGoogle Scholar
• Zhang YY, Feng HM. MEG3 suppresses human pancreatic neuroendocrine tumor cells growth and metastasis by down-regulation of Mir-183. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2017;44:345–356.
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Goff LA, Lodato S, et al. Multiple knockout mouse models reveal lincRNAs are required for life and brain development. eLife. 2013;2:e01749.
   PubMed Web of Science ®Google Scholar
• Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–1307.
   PubMed Web of Science ®Google Scholar
• Shi X, Sun M, Liu H, et al. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–166.
   PubMed Web of Science ®Google Scholar
• Li H, Wang X, Wen C, et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 2017;16:169.
   PubMed Web of Science ®Google Scholar
• Gao ZQ, Wang JF, Chen DH, et al. Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p. Biomed Pharmacother. 2017;97:809–817.
   PubMed Web of Science ®Google Scholar
• Oda D, Savard CE, Nguyen TD, et al. Culture of human main pancreatic duct epithelial cells. Vitro Cellular & Developmental Biology Animal. 1998;34:211–216.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Kojima T, Ito T, et al. Transcriptional control of tight junction proteins via a protein kinase C signal pathway in human telomerase reverse transcriptase-transfected human pancreatic duct epithelial cells. Am J Pathol. 2010;177:698–712.
   PubMed Web of Science ®Google Scholar
• Donahue TR, Tran LM, Hill R, et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2012;18:1352–1363.
   PubMed Web of Science ®Google Scholar
• Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16:259–266.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Bo H, Gong Z, et al. AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumour Biology: Journal Int Soc Oncodevelopmental Biol Med. 2016;37:729–737.
   PubMedGoogle Scholar
• Bo H, Gong Z, Zhang W, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget. 2015;6:20404–20418.
   PubMedGoogle Scholar
• Ye Y, Chen J, Zhou Y, et al. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. J Transl Med. 2015;13:137.
   PubMed Web of Science ®Google Scholar
• Nakaya Y, Sheng G. EMT in developmental morphogenesis. Cancer Lett. 2013;341:9–15.
   PubMed Web of Science ®Google Scholar
• Han X, Wang L, Ning Y, et al. Long non-coding RNA AFAP1-AS1 facilitates tumor growth and promotes metastasis in colorectal cancer. Biol Res. 2016;49:36.
   PubMed Web of Science ®Google Scholar
• Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–352.
   PubMed Web of Science ®Google Scholar
• Chen G, Fang T, Huang Z, et al. MicroRNA-133a inhibits osteosarcoma cells proliferation and invasion via targeting IGF-1R. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2016;38:598–608.
   PubMed Web of Science ®Google Scholar
• Guo J, Xia B, Meng F, et al. miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor. Tumour Biology: Journal Int Soc Oncodevelopmental Biol Med. 2014;35:1557–1564.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Y, Dong J, et al. MicroRNA-133a-3p exerts inhibitory effects on gallbladder carcinoma via targeting RBPJ. Am J Cancer Res. 2016;6:2448–2462.
   PubMed Web of Science ®Google Scholar
• Zheng K, Liu W, Liu Y, et al. MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. Oncol Lett. 2015;9:869–874.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Tian Q, He J, et al. MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor. Onco Targets Ther. 2016;9:3535–3544.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu S, Cao L, et al. miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. Oncotarget. 2017;8:86592–86603.
   PubMedGoogle Scholar
• Zhang W, Liu K, Liu S, et al. MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. Tumour Biology: Journal Int Soc Oncodevelopmental Biol Med. 2015;36:9779–9788.
   PubMed Web of Science ®Google Scholar
• Gao S, Wassler M, Zhang L, et al. MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis. 2014;232:171–179.
   PubMed Web of Science ®Google Scholar
• Wei W, Liu Y, Lu Y, et al. LncRNA XIST promotes pancreatic cancer proliferation through miR-133a/EGFR. J Cell Biochem. 2017;118:3349–3358.
   PubMed Web of Science ®Google Scholar
• Zhao L, Kong H, Sun H, et al. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. J Cell Physiol. 2018;233:4044–4055.
   Web of Science ®Google Scholar
• Wu W, Bhagat TD, Yang X, et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2013;144:956–66 e4.
   PubMed Web of Science ®Google Scholar
• Zhou XL, Wang WW, Zhu WG, et al. High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Mol Carcinog. 2016;55:2095–2105.
   PubMed Web of Science ®Google Scholar
• Luo HL, Huang MD, Guo JN, et al. AFAP1-AS1 is upregulated and promotes esophageal squamous cell carcinoma cell proliferation and inhibits cell apoptosis. Cancer Med. 2016;5:2879–2885.
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer. 2013;13:97–110.
   PubMed Web of Science ®Google Scholar
• Cai H, Yao J, An Y, et al. LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer. Oncotarget. 2017;8:32905–32917.
   PubMedGoogle Scholar
• Wang G, Pan J, Zhang L, et al. Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. Cell Prolif. 2017;50:e12389.
   Web of Science ®Google Scholar
• Cai J, Liu T, Huang P, et al. USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. Biochem Biophys Res Commun. 2017;486:184–190.
   PubMed Web of Science ®Google Scholar
• Qin Y, Dang X, Li W, et al. miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. Oncol Res. 2013;21:353–363.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wu D, Tao J, et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 2013;47:423–432.
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6:1–12.
   PubMed Web of Science ®Google Scholar
• Ioannou N, Dalgleish AG, Seddon AM, et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer. 2011;105:1554–1562.
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 2008;8:915–928.
   PubMed Web of Science ®Google Scholar
• Park E, Park SY, Kim H, et al. Membranous insulin-like growth factor-1 receptor (IGF1R) expression is predictive of poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. J Pathol Transl Med. 2015;49:382–388.
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem. 2004;92:77–91.
   PubMed Web of Science ®Google Scholar
• Ouban A, Muraca P, Yeatman T, et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 2003;34:803–808.
   PubMed Web of Science ®Google Scholar
• Valsecchi ME, McDonald M, Brody JR, et al. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118:3484–3493.
   PubMed Web of Science ®Google Scholar
• Subramani R, Lopez-Valdez R, Arumugam A, et al. Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PloS one. 2014;9:e97016.
   PubMed Web of Science ®Google Scholar
• Gong Y, Ren J, Liu K, et al. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R. World J Gastroenterol. 2015;21:2949–2958.
   PubMedGoogle Scholar
• Wang LK, Hsiao TH, Hong TM, et al. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PloS one. 2014;9:e96765.
   PubMed Web of Science ®Google Scholar
• Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 2006;20:1254–1260.
   PubMed Web of Science ®Google Scholar
• Shelton JG, Steelman LS, White ER, et al. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle. 2004;3:372–379.
   PubMed Web of Science ®Google Scholar